Stay updated on Long-Term Safety of KarXT in Alzheimer's Psychosis Clinical Trial
Sign up to get notified when there's something new on the Long-Term Safety of KarXT in Alzheimer's Psychosis Clinical Trial page.

Latest updates to the Long-Term Safety of KarXT in Alzheimer's Psychosis Clinical Trial page
- CheckyesterdayChange DetectedA new site in Vinnytsia, Ukraine (Site 8002) and the associated investigator were added, increasing the total number of locations to 429. The inclusion/eligibility language for KAR-033 was expanded to specify consent procedures, assent, and relocation considerations.SummaryDifference0.3%

- Check8 days agoChange DetectedThe page now displays a new revision label (v3.6.3) replacing the older label (v3.6.1). This indicates a small release update to the page's metadata.SummaryDifference0.0%

- Check15 days agoChange DetectedRevision: v3.6.1 replaces v3.6.0 on the page, indicating a small administrative update to the documentation. The substantive content and behavior remain unchanged.SummaryDifference0.0%

- Check22 days agoChange DetectedThe ADEPT-3 study location footprint was updated to 428 locations with two new sites added (Bucharest, Romania and Xi’an, China) and the total locations increased accordingly. Additionally, several existing sites were removed, indicating adjustments to where participants may enroll.SummaryDifference0.6%

- Check30 days agoChange DetectedNew user guidance links were added to the page, including Check who can join, Find Contact Information, How to Read a Study Record, Common Questions, and How to Join a Study. The Intervention/Treatment label formatting was standardized and the page revision updated from v3.5.5 to v3.6.0.SummaryDifference0.1%

- Check37 days agoChange DetectedThe study record now includes new sites in Vinnytsia, Uzhhorod, Lviv, and Seoul, increasing the total number of locations to 426, and it reflects updated statuses for several local institutions (including completed/withdrawn ones) and the addition of Site 1252 in Shelby, NC.SummaryDifference0.5%

Stay in the know with updates to Long-Term Safety of KarXT in Alzheimer's Psychosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Long-Term Safety of KarXT in Alzheimer's Psychosis Clinical Trial page.